Document ID: chunk:federal_register_of_legislation:F2025C00126:schedule:1:p17
Version: federal_register_of_legislation:F2025C00126
Segment Type: schedule
Provision Reference: sch 1 (pt 17/23)
Character Range: 112289–119842

Viatris                                    after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 10 added together
Ramipril                                                                            Tablet 2.5 mg                                                                                                          Oral                        Ramipril Viatris                                    after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 2.5 added together
Ramipril                                                                            Tablet 5 mg                                                                                                            Oral                        Ramipril Viatris                                    after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 5 added together
Ramipril with felodipine                                                            Tablet 2.5 mg-2.5 mg (modified release)                                                                                Oral                        Triasyn 2.5/2.5                                     between 1 February 2025 and 30 September 2025—0 months stock by reference to usual PBS demand
Risedronic acid                                                                     Tablet containing risedronate sodium 150 mg                                                                            Oral                        APO‑Risedronate                                     3 months stock by reference to usual demand
Risperidone                                                                         Tablet 3 mg                                                                                                            Oral                        APO‑Risperidone                                     (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
                                                                                                                                                                                                                                                                                           (b) after 31 December 2023—3.5 months stock by reference to usual demand
Risperidone                                                                         Tablet 3 mg                                                                                                            Oral                        Rispa                                               3 months stock by reference to usual demand
Rizatriptan                                                                         Tablet (orally disintegrating) 10 mg (as benzoate)                                                                     Oral                        APO-RIZATRIPTAN ODT                                 4 months stock by reference to usual demand of both Rizatriptan ODT APOTEX and APO-RIZATRIPTAN ODT added together
Rosuvastatin                                                                        Tablet 10 mg (as calcium)                                                                                              Oral                        APO-Rosuvastatin                                    6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-Rosuvastatin added together
Rosuvastatin                                                                        Tablet 20 mg (as calcium)                                                                                              Oral                        APO-ROSUVASTATIN                                    4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Rosuvastatin                                                                        Tablet 40 mg (as calcium)                                                                                              Oral                        APO-ROSUVASTATIN                                    4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Rosuvastatin                                                                        Tablet 5 mg (as calcium)                                                                                               Oral                        APO-ROSUVASTATIN                                    6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Roxithromycin                                                                       Tablet 150 mg                                                                                                          Oral                        APX‑Roxithromycin                                   4 months stock by reference to usual demand
Roxithromycin                                                                       Tablet 300 mg                                                                                                          Oral                        APX‑Roxithromycin                                   (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand
                                                                                                                                                                                                                                                                                           (b) after 31 December 2023—5 months stock by reference to usual demand
Sevelamer                                                                           Tablet containing sevelamer carbonate 800 mg                                                                           Oral                        ARX-SEVELAMER                                       4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together
Sevelamer                                                                           Tablet containing sevelamer carbonate 800 mg                                                                           Oral                        Sevelamer Apotex                                    4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together
Sodium acid phosphate                                                               Tablet, compound effervescent, equivalent to 500 mg phosphorus                                                         Oral                        PHOSPHATE PHEBRA                                    6 months stock by reference to usual PBS demand
Sotalol                                                                             Tablet containing sotalol hydrochloride 160 mg                                                                         Oral                        Cardol                                              (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand
                                                                                                                                                                                                                                                                                           (b) after 31 December 2023—1.5 months